Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    CYCC

CYCLACEL PHARMACEUTICALS INC

(CYCC)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

CYCLACEL PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 06:32pm EDT
Item 3.01    Notice of Delisting or Failure to Satisfy a Continued Listing Rule
             or Standard; Transfer of Listing.



On January 8, 2019, Cyclacel Pharmaceuticals, Inc. (the "Company") received a written notification from The NASDAQ Stock Market LLC ("NASDAQ") indicating that the Company was not in compliance with NASDAQ Listing Rule 5550(a)(2) because the minimum bid price of the Company's shares of common stock was below $1.00 per share for the previous 30 consecutive business days.

Pursuant to the NASDAQ Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until July 7, 2019, to regain compliance with the minimum bid price requirement. During the compliance period, the Company's shares of common stock will continue to be listed and traded on The NASDAQ Capital Market. To regain compliance, the closing bid price of the Company's shares of common stock must meet or exceed $1.00 per share for at least ten consecutive business days during this 180-day grace period.

If the Company is not in compliance by July 7, 2019, the Company may be eligible for an additional 180-calendar day compliance period. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The NASDAQ Capital Market, except for the minimum bid price. In addition, the Company would be required to notify NASDAQ of its intent to cure the minimum bid price deficiency by effecting a reverse stock split, if necessary.

If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by NASDAQ, NASDAQ will provide notice that the Company's shares of common stock will be subject to delisting. The Company would then be entitled to appeal NASDAQ's determination to a NASDAQ Hearings Panel and request a hearing.

The Company intends to consider available options to resolve the noncompliance with the minimum bid price requirement. No determination regarding the Company's response has been made at this time. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other NASDAQ listing criteria.



Forward-Looking Statements


Certain statements in this Current Report on Form 8-K constitute forward-looking statements that involve a number of known and unknown risks, uncertainties and other factors that may cause such forward-looking statements not to be realized. Factors that could cause actual results to differ materially from the forward-looking statements include changes to the listing standards, policies and procedures of the NASDAQ Capital Market, fluctuations in the Company's general financial and operating results, changes in the Company's liquidity and capital resources, declines in the market price of the Company's shares of common stock, changes in the capital markets, competition, and general and industry-specific economic conditions. We believe these factors include but are not limited to those described under "Risk Factors" in our Annual Report on Form 10-K, as such factors may be updated from time to time in our periodic filings with the Securities and Exchange Commission (the "SEC"), which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Current Report on Form 8-K, our Annual Report on Form 10-K and other filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CYCLACEL PHARMACEUTICALS I
03/25Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Tr..
GL
03/20Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financi..
GL
03/13Cyclacel to Participate in 31st Annual ROTH Conference March 18-19
GL
03/12CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
03/06CYCLACEL PHARMACEUTICALS : Announces Abstracts Selected for Presentation at the ..
AQ
03/05Cyclacel Announces Abstracts Selected for Presentation at the American Associ..
GL
02/06CYCLACEL PHARMACEUTICALS : to Present at the 2019 BIO CEO and Investor Conferenc..
AQ
02/05Cyclacel Pharmaceuticals to Present at the 2019 BIO CEO & Investor Conference
GL
01/11CYCLACEL PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Con..
AQ
01/08CYCLACEL PHARMACEUTICALS : Reviews 2018 Achievements and Announces Key Business ..
AQ
More news
Financials ($)
Sales 2018 -
EBIT 2018 -9,57 M
Net income 2018 -7,64 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 0
Capi. / Sales 2019 0
Capitalization 11,9 M
Chart CYCLACEL PHARMACEUTICALS INC
Duration : Period :
Cyclacel Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYCLACEL PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 7,00 $
Spread / Average Target 637%
EPS Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC57.02%12
GILEAD SCIENCES1.98%81 365
VERTEX PHARMACEUTICALS9.55%47 003
REGENERON PHARMACEUTICALS5.76%42 410
GENMAB7.54%10 705
SAREPTA THERAPEUTICS INC8.97%8 762